BioNTech (NASDAQ:BNTX) Price Target Raised to $113.00

BioNTech (NASDAQ:BNTX) had its target price raised by analysts at HC Wainwright from $107.00 to $113.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 24.34% from the stock’s current price.

Several other research firms have also issued reports on BNTX. UBS Group lowered their price target on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 27th. TD Cowen raised their price target on BioNTech from $95.00 to $98.00 and gave the stock a “hold” rating in a report on Tuesday. The Goldman Sachs Group reduced their price target on BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 28th. JPMorgan Chase & Co. dropped their price objective on BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a report on Friday, March 22nd. Finally, BMO Capital Markets reduced their target price on BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a report on Tuesday. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $118.82.

BioNTech Stock Performance

Shares of BNTX stock opened at $90.88 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.26 and a current ratio of 9.43. The firm has a market cap of $21.60 billion, a price-to-earnings ratio of 22.06 and a beta of 0.25. BioNTech has a 52 week low of $85.21 and a 52 week high of $125.83. The firm’s 50-day simple moving average is $90.50 and its two-hundred day simple moving average is $95.99.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing the consensus estimate of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $2.04 billion. As a group, equities analysts forecast that BioNTech will post -1.74 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BNTX. Baillie Gifford & Co. boosted its holdings in shares of BioNTech by 1.0% in the 4th quarter. Baillie Gifford & Co. now owns 8,689,182 shares of the company’s stock worth $917,056,000 after purchasing an additional 86,343 shares in the last quarter. Primecap Management Co. CA boosted its stake in BioNTech by 2.8% in the fourth quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock worth $502,735,000 after buying an additional 131,490 shares in the last quarter. Harding Loevner LP bought a new position in BioNTech during the fourth quarter valued at approximately $410,984,000. Flossbach Von Storch AG raised its stake in shares of BioNTech by 1.0% during the fourth quarter. Flossbach Von Storch AG now owns 3,548,660 shares of the company’s stock worth $374,526,000 after acquiring an additional 35,445 shares in the last quarter. Finally, Capital World Investors lifted its holdings in shares of BioNTech by 1.5% in the 4th quarter. Capital World Investors now owns 938,747 shares of the company’s stock worth $99,075,000 after acquiring an additional 14,027 shares during the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.